Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination with a Second, Unmanipulated Cord Blood Unit in Patients with Sickle Cell Disease

Trial Profile

Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination with a Second, Unmanipulated Cord Blood Unit in Patients with Sickle Cell Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Cord blood stem cell therapy (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Gamida-Cell
  • Most Recent Events

    • 24 May 2017 Planned number of patients changed from 10 to 15.
    • 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 06 Dec 2016 Preliminary results in the first 8 patients, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top